CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI

This study has been completed.
Sponsor:
Information provided by:
Lantheus Medical Imaging
ClinicalTrials.gov Identifier:
NCT00162331
First received: September 9, 2005
Last updated: April 14, 2011
Last verified: April 2011

September 9, 2005
April 14, 2011
January 2005
July 2007   (final data collection date for primary outcome measure)
To better understand the interactions between the abnormalities in blood supply from the small vessels of the heart to the heart muscle after a heart attack and the changes in heart size 6 months after the heart attack.
Same as current
Complete list of historical versions of study NCT00162331 on ClinicalTrials.gov Archive Site
  • To estimate the frequency of residual ischemia as assessed by stress myocardial perfusion imaging (MPI) in patients undergoing primary PCI for AMI.
  • To estimate the 6-month cardiac event rates (composite of death, another heart attack, hospitalization for heart failure, and irregular heart beats requiring treatment).
  • To determine the relationship between changes (from baseline) in LV systolic volume index and LVEF, as measured by gated SPECT imaging 6 months following reperfusion, and the presence and severity of residual ischemia.
  • To measure the performance of angiographic parameters of success of reperfusion therapy (TIMI frame count and TIMI myocardial perfusion grade) in predicting the presence of residual ischemia.
Same as current
Not Provided
Not Provided
 
CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI
AIR-MI: Assessment of Ischemia and Remodeling Following Acute Myocardial Infarction

The purpose of this clinical study is to learn if there are any changes in how blood gets to your heart muscle and if your heart size changed after your heart attack.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Myocardial Infarction
Drug: Technetium Tc99m Sestamibi
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
74
July 2007
July 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Undergoing primary or rescue PCI for acute MI with ECG evidence of a large territory at risk.

Exclusion Criteria:

  • History of prior MI or CABG surgery, persistent LBBB, Atrial Fibrillation, End stage renal disease, Weight > 350 lbs.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Brazil,   Canada
 
NCT00162331
CARDIOLITE-413
No
Qi Zhu, MD Sr. Medical Director, Lantheus Medical Imaging
Lantheus Medical Imaging
Not Provided
Study Director: Qi Zhu, MD Lantheus Medical Imaging
Lantheus Medical Imaging
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP